BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20838200)

  • 1. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
    Kalra A; Cooley C; Palaniswamy C; Kalra A; Zanotti-Cavazzoni SL
    Am J Ther; 2012 Nov; 19(6):e189-92. PubMed ID: 20838200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis.
    Shino M; Takahashi K; Murata T; Iida H; Yasuoka Y; Furuya N
    Am J Otolaryngol; 2011; 32(6):624-6. PubMed ID: 21324549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valsartan-induced angioedema.
    Irons BK; Kumar A
    Ann Pharmacother; 2003; 37(7-8):1024-7. PubMed ID: 12841812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angioedema: 6 years experience with fourteen cases.
    Taki M; Watanabe H; Hasegawa T; Bamba H; Shimada T; Hisa Y
    Auris Nasus Larynx; 2010 Apr; 37(2):199-204. PubMed ID: 19709832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Malde B; Regalado J; Greenberger PA
    Ann Allergy Asthma Immunol; 2007 Jan; 98(1):57-63. PubMed ID: 17225721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angioedema and photosensitive rash induced by valsartan.
    Frye CB; Pettigrew TJ
    Pharmacotherapy; 1998; 18(4):866-8. PubMed ID: 9692664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olmesartan medoxomil-induced angioedema.
    Nykamp D; Winter EE
    Ann Pharmacother; 2007 Mar; 41(3):518-20. PubMed ID: 17341528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract]   [Full Text] [Related]  

  • 13. Valsartan, captopril, or both in myocardial infarction.
    Moshenyat R; Kupfer Y; Tessler S
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
    Gulec M; Caliskaner Z; Tunca Y; Ozturk S; Bozoglu E; Gul D; Erel F; Kartal O; Karaayvaz M
    Allergol Immunopathol (Madr); 2008; 36(3):134-40. PubMed ID: 18680700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers].
    Roskiewicz F; Andriamanana I; Gras-Champel V; Andrejak M; Massy ZA
    Nephrol Ther; 2007 Jun; 3(3):89-95. PubMed ID: 17540310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
    Chiu AG; Krowiak EJ; Deeb ZE
    Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.